-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Jefferies Downgrades Landos Biopharma to Underperform, Lowers Price Target to $0.1

Benzinga · 01/06/2023 06:09
Jefferies analyst Chris Howerton downgrades Landos Biopharma (NASDAQ:LABP) from Hold to Underperform and lowers the price target from $0.2 to $0.1.